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Abstract
Purpose—To assess the association between RT-induced changes in computed tomography 
(CT)-defined lung tissue density and pulmonary function tests (PFTs).
Methods and Materials—Patients receiving incidental partial lung irradiation were 
prospectively assessed for global (PFTs) and regional (CT and SPECT [single photon emission 
computed tomography] scans) lung function pre- and serially post-RT. The percent reductions in 
PFTs and the average changes in lung density were compared (Pearson correlations) in the overall 
group and subgroups based on various clinical factors. Comparisons were also made between the 
CT- and SPECT-based computations using U test.
Results—From 1991–2004, 343 patients were enrolled. Of these, 111 patients had a total of 203 
concurrent post-RT evaluations of changes in lung density and PFTs available for analyses, and 81 
patients had a total of 141 concurrent post-RT SPECT images as well. The average increases in 
lung density were related to the percent reductions in PFTs, albeit with modest correlation 
coefficients (r) (range, 0.20 ~ 0.43). The analyses also indicate that the association between lung 
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density and PFT changes is essentially equivalent to the corresponding association with SPECT-
defined lung perfusion.
Conclusion—There is a weak quantitative association between the degree of increase in lung 
density as defined by CT and percent reduction in PFTs.
Keywords
Radiation induced lung injury; Lung density; Computed tomography; Pulmonary function tests; 
Single photon emission computed tomography defined lung perfusion
INTRODUCTION
Radiation-induced lung injury is common in patients receiving thoracic radiotherapy (RT) 
1–3. The study of RT-induced lung injury is complicated by the multiple endpoints 
frequently considered (e.g., radiologic vs. symptomatic vs. functional) 4. Interpretation of 
the literature can be challenging since the reported frequency of injury is highly dependent 
on the endpoint considered 5–8, which may be impacted by potentially confounding clinical 
factors 9–12, and the association between the different endpoints is not entirely clear.
In 1991, we initiated a prospective clinical study to serially monitor RT-induced changes in 
regional lung density with computed tomography (CT), regional perfusion with single 
photon emission computed tomography (SPECT), pulmonary function tests (PFTs), and 
symptoms. We have previously reported on the association between changes in pulmonary 
symptoms and dosimetric predictors (i.e., V30 and mean lung dose) 1, the degree of changes 
in PFTs 4, 6-minute walk test (6MWT) 13, lung density 5, and perfusion 6. We have also 
tried to relate changes in PFTs to the extent of regional perfusion changes 14. We herein 
assess the association between quantitative changes in lung density and changes in PFTs. 
We hypothesize that patients who demonstrate greater changes in lung density will also 
manifest larger declines in PFTs.
METHODS
Since 1991, we initiated an Institutional Review Board approved prospective clinical trial to 
better understand RT-induced lung injury. Written informed consent was obtained. As part 
of this study, patients underwent pre-RT and serially (typically at 6-month intervals) post-
RT PFTs, thoracic CT (to assess regional lung density), SPECT (to assess regional 
perfusion), and assessment of symptoms as previously described 4, 5, 15. The protocol 
called for CT and PFT assessment to be done at the same day. However, this was not always 
possible due to scheduling/logistical issues. Patients with post-RT anatomic changes that 
would confound the analysis were excluded, including those with radiographic evidence of 
tumor progression and/or pleural effusions. Patients with alternative reasons for declines in 
PFTs (i.e., COPD flair) were similarly excluded. Only patients with evaluations of changes 
in both lung density and PFTs assessed within 1 week of each other were studied.
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A CT scan was acquired for each patient in the treatment position, typically in an 
immobilization device. Patients with lung cancer typically underwent three-dimensional 
(3D) treatment planning. Patients planned using two-dimensional (2D) simulation 
techniques had their images imported into the treatment planning system (PLUNC: Plan 
University of North Carolina, Chapel Hill, NC). For all patients, the pre-RT CT dataset was 
used to calculate the 3D dose distribution utilizing tissue density inhomogeneity corrections. 
The lungs were segmented on the CT images automatically by the PLUNC using a 
thresholding method at a CT number between −300 and −400 Hounsfield units (HU) 5, and 
edited manually based on visual inspection. All computations of changes in lung density and 
perfusion described below were conducted within these CT-defined lungs. The intra-thoracic 
gross tumor was excluded from the lung. All doses refer to physical doses, without 
adjustments for fraction size.
The radiation technique for patients enrolled onto this protocol has previously been 
described 16. Patients with lung cancer generally received opposed anterior/posterior fields 
to 40–45 Gy; off-cord obliques boost to ≈ 66 Gy; all given in 2 Gy daily fractions. 15 
patients received a hyperfractionated concurrent boost: 1.25 Gy BID to a clinical target 
volume and 1.6 Gy BID to gross disease (6-hour minimum inter-fraction interval) to 73.6 
Gy. Patients with breast cancer received tangents to 46–50 Gy in 2 Gy daily fractions. 
Patients with lymphoma received anterior/posterior fields to ≈ 20–40 Gy in 1.5–1.8 Gy 
daily fractions.
PFTs
The PFTs included forced expiratory volume in 1 second (FEV1) and diffusion capacity for 
carbon monoxide (DLCO) 15. DLCO was corrected for hemoglobin 15, unless otherwise 
noted. The analysis was repeated using uncorrected DLCO to include data from patients 
without hemoglobin measurements. All values were considered as percentage of predicted 
(based on sex, height, and weight). Declines in PFTs were described as percent reduction 
from the pre-RT value, i.e., Percent Reduction in PFT = (1 − post/pre) * 100
CT
Each patient’s post-RT CT scans were manually registered to the pre-RT CT scan, based 
primarily on the lung volumes, using PLUNC. Registrations were performed in three 
dimensions. Post-RT scans were performed on a CT unit within radiation oncology 
department in the treatment position.
The absolute change in CT density (ΔCT), within each region of lung receiving a similar RT 
dose (d) was computed; with doses bin of 5 Gy intervals (e.g., 0–5, 5.1–10, etc.). Mean 
density change (i.e., volume-weighted) post-RT in the entire lung for each post-RT CT 
(relative to pre-RT CT) was computed. Mathematically,
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where Vd is the volume of lung irradiated to dose d, and ΔCTd is the absolute change in CT 
number at dose d. This similar approach has been used to pool data regarding changes in 
regional perfusion assessed by SPECT 14.
SPECT
We have previously related the SPECT perfusion changes to PFTs declines 14. We herein 
include SPECT data to assess if the association between average changes in perfusion 
throughout the lung and PFT declines is “better or worse” than the association between 
changes in CT density and PFT declines.
SPECT images were registered with the planning CT and, hence, the 3D dose distribution. 
The percent SPECT counts in each dose bin (e.g., 0–5 Gy, 5.1–10 Gy) was used to generate 
a “dose SPECT-count histogram” (or dose-function histogram, DFH). Each patient’s pre- 
and post-RT DFHs were quantitatively compared to derive the patient-specific dose 
response curve (DRC) at each time point, demonstrating changes in regional perfusion vs. 
regional dose 11, 15. Assuming no RT-induced change in “low”-dose regions, the number of 
SPECT counts at all sites was normalized to the number of counts in areas receiving ≤ 5.0 
Gy (0–5 Gy dose bin) 14. The percent change in perfusion throughout the lung was 
calculated as:
where Vd is the volume of lung irradiated to dose d, and Rd is the percent reduction in 
regional perfusion at dose d.
Data analysis
Many patients underwent only one post-RT assessment while others underwent repeated 
assessments. The overall group analysis described below was performed twice.
First, all data were considered including repeated post-RT measures at different time points 
from the same patient. Second, only one representative post-RT assessment was considered 
per patient. For this, several methods were used:
a. Considering data only at a specific post-RT follow-up interval, as used in a prior 
analysis 6;
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b. Considering the average of post-RT data from a single patient; and
c. Considering the maximum change post-RT, i.e. trough in post-RT PFTs or peak in 
post-RT lung density changes.
The analysis was initially conducted on the entire patient population. Due to the potential 
impact of possible confounding clinical factors on lung function, analyses were repeated in 
subgroups based on the smoking history, tumor type (lung vs. non-lung), and the presence or 
absence of RT-associated pulmonary symptoms (≥ grade 2, i.e. requiring steroids, or worse). 
Further, since prior analysis demonstrated that patients with large central tumors and 
adjacent hypoperfusion (based on pre-RT SPECT scan) have a ≈ 50% probability of 
experiencing improvements in PFTs post RT 17, analysis was repeated excluding these 
patients. Since there may be surgery- or chemotherapy-associated changes in lung density, 
the analysis was repeated in subgroups based on pre-RT surgery or chemotherapy 9, 18–20. 
Last, the analysis was repeated using recognized PFT cut-offs (FEV1 < 2L, ≥ 2L; DLCO < 
60%, ≥ 60% predicted) 21, since pre-RT PFTs might be considered for clinical decisions in 
routine treatments.
To assess if the association between mean perfusion changes and PFTs is “better or worse” 
than the association between CT density changes and PFTs, we identified a subset of 
patients with both pre- and post-RT SPECT and CT images. The results for the CT- and 
SPECT-based computations described above were compared.
Statistics
For each analysis, the average changes in lung density were related to the percent reductions 
in PFTs using the Pearson correlation. A comparison was made between correlation 
coefficients (r) using U test after Fisher’s z′ transformation.
RESULTS
343 patients were enrolled between 1991 and 2004. Of these, 111 patients were evaluable 
with a total of 203 concurrent post-RT evaluations of changes in both CT density and PFTs 
for analyses (table 1). The remainder of enrolled patients was unevaluable for a variety of 
reasons indcluding progressive tumor/death (n = 83), non-malignant pulmonary events (e.g., 
COPD flair, n = 35), post-RT surgery (e.g., pneumonectomy, n = 3), logistic/technical issues 
(n = 80), lost follow-up (n = 17), and/or other reasons (n = 14). Amongst patients with 
evaluable PFT data, hemoglobin values were available in 191 instances (94.1%). The 
association between average increases in lung density and percent reductions in DLCO and 
FEV1 for the overall group are shown in Table 2 and Figure 1. Significant correlations, 
albeit with modest correlation coefficients (r), were noted. Similar results were found for 
corrected DLCO (data not shown).
In 62 patients, >1 post-RT measurement was performed. Multisampling in a single patient 
may introduce bias. The data were therefore reanalyzed considering a single post-RT value 
per patient. When analysis was restricted to the 72 patients with evaluable data at 
approximately 6 months post-RT, or the post-RT data from the 62 patients with repeated 
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measures was averaged, or the maximum change was considered, the findings were largely 
similar (see Figure 2 (a–d) and Table 2).
The corresponding data for patients in various subgroups are shown in Table 3. Patients 
without smoking history, with non-lung cancer malignancies, and with pulmonary 
symptoms, make up only a small fraction of the population. When these patients were 
excluded from the analysis, the overall results did not change. The results in other subgroups 
based on the presence or absence of a central tumor and adjacent hypoperfusion, the use of 
surgery or chemotherapy, and pre-RT PFTs did not appear to markedly influence the results. 
However, the data are somewhat erratic in some of the smaller subgroups.
In the entire population, 81 patients had a total of 141 concurrent post-RT SPECT and CT 
images. Only one post-RT assessment was made in 38 patients and multiple measures in the 
other 43. The association between the percent reduction in PFTs and the average increase in 
lung density, or SPECT perfusion reduction for this subgroup are shown in Table 4 and 
Figure 3. Significant correlations were revealed for both CT- and SPECT- based 
computations. The correlation coefficients (r) were modest, but appeared slightly higher for 
the association between changes in PFTs and CT density, than that for corresponding 
association with changes in SPECT perfusion. However, the difference is statistically 
insignificant (p = 0.25, 0.25, and 0.23 for DLCO, corrected DLCO, and FEV1, respectively).
DISCUSSION
RT-induced pulmonary injury is common after thoracic irradiation. The reported incidence 
of such injury varies widely, and is primarily dependent on the chosen endpoint. Among 
those patients receiving RT for thoracic malignancies, approximately 5–30% develop 
symptomatic radiation pneumonitis (RP), 50–100% develop radiologic evidence of regional 
injury, and 50–90% experience declines in pulmonary function 4, 22–25.
Several studies have successfully related 3D dose-volume histogram (DVH)-based metrics 
(e.g., the percent lung volume receiving ≥20–30Gy) to the rates of symptomatic radiation 
pneumonitis 1–3, 23. More recent studies, some using a larger number of beam orientations, 
have implicated the lung volume receiving 5–13 Gy 22, 26, 27. Such volume-based metrics 
are commonly used to evaluate treatment plans and they are considered to be 
“physiologically logical” since the lung’s functional subunits are structured in parallel with 
each other (i.e., each region of the lung may function relatively independently). Therefore, 
it’s reasonable to postulate that percent changes in global lung function (i.e., assessed by 
PFTs) would correlate with the average changes in regional lung function assessed by 
SPECT or CT. Our group, and investigators at the Netherlands Cancer Institute (NKI), have 
used SPECT lung perfusion scans to relate changes in regional dose. In independent 
analyses, from both institutions, DRCs from many patients were summed to generate 
population-based DRCs 11, 12. Studies from Duke University 16 and NKI 28 have 
attempted to quantitatively relate post-RT declines in PFTs to the sum of regional reductions 
in perfusion and/or ventilation (either actual reductions or predicted reductions based on 
population DRCs). Overall, statistically significant correlations existed between the sum of 
regional injuries and reductions in PFTs 14, 16, 28. However, the correlations were only 
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fair, suggesting that changes in perfusion/ventilation alone are not sufficient to accurately 
predict the changes in PFTs. A study from M.D. Anderson Cancer Center suggested that 
there may be an association between grade ≥ 2 pulmonary symptoms and a DLCO loss of > 
30% 29.
An alternative method to assess RT-induced regional lung injury is tissue density assessed 
with conventional CT. Quantitative analyses of changes in lung density have been reported 
previously by Duke 5, NKI 30, Princess Margaret Hospital (PMH) 20, and others 10, 24, 31. 
The current study attempted to relate changes in individual patient’s lung density with 
changes in the PFTs.
The association between changes in lung density and PFT values
The current analysis suggests that there is a quantitative association between the degree of 
increase in lung density as defined by CT and declines in PFTs. This was true in the overall 
group as well as in most of the subgroups considered. However, the correlations are weak. 
This suggests that other factors beyond regional tissue density impact on PFTs. This might 
also suggest that CT density and PFTs may not be ideal measures of regional and global 
lung function, respectively. Further, there likely are additional clinical factors that confound 
changes noted on CT and with PFTs.
One of the reasons that we have included SPECT in our studies is our belief that SPECT 
imaging provides a more physiologic assessment of lung function than does CT. However, 
we have observed that the average of SPECT perfusion changes appears not to be better 
correlated with PFT changes than the average of CT density changes 14.
Handling of repeated assessments
Several measures were taken to consider the potential bias introduced by multiple data 
points from a single patient. Restriction of our analyses to data at 6 months post-RT 
modestly improved our correlation coefficients. When multiple assessments from a single 
patient were averaged, and combined with data from patients with single assessment to form 
a new dataset, the correlations were still significant for all comparisons. As described, 
alternative methods to address these multiple data points were also considered, and in all 
cases, the correlation coefficients were modest.
Potential confounding clinical factors
Previous studies have shown that global lung function is affected by factors unrelated to 
subsequent RT (e.g., smoking history, pre-RT surgery, etc.) 9, 17–20, 31. For example, we 
observed that patients with SPECT perfusion defects adjacent to a central mediastinal mass 
might have improved PFTs following RT 17. Such phenomena may limit our ability to relate 
increases in lung density and PFTs declines. In the current analysis, results were essentially 
similar in all subgroups. Interestingly, the correlation coefficients appeared to increase when 
the data from patients with centrally located tumor (i.e. those more likely to have regional 
dysfunction due to mass-effect from the tumor) were excluded from the analyses. This 
suggests that it is logical to consider these patients independently as they appear to 
potentially confound the analysis.
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The data were similar in the groups with and without chemotherapy. In the current analysis, 
most lung cancer patients received platinum-based chemotherapy prior to RT. There are data 
to suggest that certain chemotherapeutics can increase the probability of pulmonary fibrosis, 
and therefore might increase lung density 19, 20. Rosen et al. 19 noted a complex 
interaction between chemotherapy and radiation fractionation. Higher rates of CT-defined 
pulmonary fibrosis were seen in patients treated with BID vs. QD fractionation (when given 
with cisplatin and etoposide [PE] chemotherapy). However, BID radiation plus cisplatin, 
ifosfamide, and etoposide (PIE) chemotherapy (different doses and schedules than the PE 
treated patients) had a relatively low rate of fibrosis. Chemotherapy can also affect PFTs, the 
extent of which has not been firmly established 9, 18, 31, 32. Generally, the impact of 
chemotherapy on RT-induced changes in lung density and PFTs might depend on the 
regimens used and the timing of chemoradiation 32. Due to the increasing use of 
chemotherapy in patients with tumors in and around the thorax, more work is necessary to 
better understand the interactions between chemotherapy and RT-induced lung injury.
The results did not change much when the analysis was repeated using recognized PFTs cut-
offs. A prior analysis from our institution 33 and an additional study from RTOG 34, did not 
implicate pre-RT PFT values as predictors for subsequent development of pulmonary 
toxicity. Thus, the importance of pre-RT PFT’s remains uncertain.
Implications of the current study
The association between the average increase in lung density and PFTs reductions does not 
prove a “cause and effect”. Nevertheless, the association does support the general hypothesis 
that percent changes in global lung function may represent the average changes in regional 
lung function (i.e., that the lung is structured in “parallel”). The latter may be related to 
radiologic changes such as reductions in regional perfusion or an increase in CT density.
Limitations of this study
This study has several limitations. First, differences in the acquisition of pre-RT CT scans 
and post-RT follow-up scans may impact the accuracy of CT and SPECT registration 35. 
Planning CT scans were performed in the treatment position with or without immobilization 
devices while follow-up CT and SPECT scans were obtained without such devices. Thus, 
small deviations in CT registration may have caused errors in the computation of both the 
dose and volume of the lung, and therefore affect the certainty of CT density and perfusion 
changes. However, since the RT fields used in these cases were generally large, modest 
registration inaccuracies are not likely to markedly alter the results. Further, all post-RT CT 
scans were performed on a flat table top, and all SPECT and CT scans were performed in 
the approximate treatment position.
Second, we did not consider the potential impact of respiratory motion, fibrotic retraction, 
and other pathophysiological changes 24, 36. These factors might introduce healthy lung 
tissue into the originally-irradiated volume resulting in computation errors in dose and 
volume, lung density differences, and perfusion changes.
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Third, the timing/frequency of follow-up CT and SPECT and PFT was quite variable, 
despite attempts to perform them at similar intervals after RT. In practice, it was logistically 
challenging to study these patients. Many patients developed progressive disease and 
became unevaluable. Even evaluable patients had concurrent medical and social/logistical 
factors making it difficult to obtain the necessary tests in this relatively-ill patient 
population.
Future research and conclusions
The correlations between the average increases in lung density and PFTs declines are weak. 
Thus, ability to predict percent changes in PFTs based on anticipated changes in average 
regional lung density (or perfusion) appears limited. Future studies will consider 
assessments of regional injury based on both density and perfusion, and include biological/
functional information into our models 37, 38. In addition, dose-volume relations, and 
additional clinical variables (e.g., prior-RT lung function, Performance Status, co-existing 
diseases, etc.) should also be considered. On all accounts, more accurate models are needed 
to predict the risk of clinically relevant RT-induced lung injury. Development of predictive 
models might allow radiation oncologists to better optimize RT treatment planning and the 
therapeutic ratio.
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Comparison between the average changes in lung density and percent reductions in PFTs for 
all observations (n = 203).
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Comparison between the average changes in lung density and percent reductions in PFTs: 
(a) for patients at 6-month post-RT follow-up interval; (b) for all patients, with the results 
averaged for the 62 patients with > 1 assessments; (c) for all patients, with the maximum 
change in PFTs post-RT considered for the 62 patients with > 1 assessment; (d) for all 
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patients, with the maximum change in lung density post-RT considered for the 62 patients 
with > 1 assessment.
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Comparison between the average increases of CT-based lung density, the average decreases 
of SPECT-based lung perfusion, and their associations with percent reductions in PFTs for 
patients with concurrent PFTs, CT, and SPECT scans.
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Table 1
Patient Characteristics
Characteristics (n = 111) N
Sex
 Male 52 (47%)
 Female 59 (53%)
Median age in years (range) 62 (22–87)
Tumor type
 Lung cancer 91 (82%)
 Breast cancer 13 (12%)
 Lymphoma 3 (3%)
 Others* 4 (3%)
Smoking history 92 (83%)
 Median pack years (range) 40 (0–150)
Location of tumor (lung cancer)
 Central 59 (53%)
 Peripheral 32 (29%)
 COPD 23 (21%)
Thoracic surgery prior to RT 33 (30%)
Chemotherapy† 55 (50%)
Mean lung dose (Gy) 16.8 (4.2–35.5)
Symptomatic radiation pneumonitis§
 Grade 0–1 84 (76%)
 Grade 2–3 27 (24%)
*
Kidney, melanoma, esophagus, thymus.
§
A modified version of the Common Toxicity Criteria of the National Cancer Institute was used 20, 30.
†
Most are platinum-based regimens received by lung cancer patients prior to RT.
Abbreviations: COPD = Chronic obstructive pulmonary disease; RT = radiation therapy.






















Ma et al. Page 17
Table 2
Correlation between the average increases in lung density and reductions in PFTs for the overall group
No. of tests r p-value
Overall – all data considered
3 to 24 months post-RT
CT vs. DLCO 203 0.26 <0.001
CT vs. FEV1 203 0.34 <0.001
6-month follow-up interval
CT vs. DLCO 72 0.29 0.015
CT vs. FEV1 72 0.35 0.003
Averaged data over all follow-up intervals CT vs. DLCO 111 0.23 0.016
CT vs. FEV1 111 0.36 <0.001
At the time of maximum PFT decline
CT vs. DLCO 111 0.20 0.034
CT vs. FEV1 111 0.30 0.001
At the time of maximum density increase
CT vs. DLCO 111 0.17 0.070
CT vs. FEV1 111 0.37 <0.001
Abbreviations: DLCO = diffusion capacity for carbon monoxide; FEV1 = forced expiratory volume in 1 second; PFT = pulmonary function tests
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